<DOC>
	<DOCNO>NCT00564694</DOCNO>
	<brief_summary>RATIONALE : Collecting information quality life patient colorectal cancer may help doctor learn disease . PURPOSE : This clinical trial study European Organization Research Treatment Cancer ( EORTC ) quality-of-life-questionnaire patient colorectal cancer .</brief_summary>
	<brief_title>Studying Quality Life Questionnaire Patients With Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To test reliability clinical psychometric validity European Organization Research Treatment Cancer ( EORTC ) quality life questionnaire ( QLQ-CR29 ) international sample patient colorectal cancer . OUTLINE : This multicenter study . Patients stratify predetermine clinically distinct group ( colon cancer surgery v colon cancer undergo adjuvant chemotherapy v rectal cancer undergo neoadjuvant radiotherapy v rectal cancer anterior resection temporary stoma v rectal cancer abdominoperineal excision rectum v colorectal cancer undergo palliative chemotherapy ) . Quality-of-life data collect alongside standard outcome patient undergo treatment colorectal cancer . Patients complete European Organization Research Treatment Cancer ( EORTC ) quality life questionnaire ( QLQ-C30 ) , revise colorectal cancer module ( QLQ-CR29 ) , case report form clinical sociodemographic data , debrief questionnaire different time point , , treatment . Some patient complete set questionnaire later time point assess sensitivity change time test-retest reliability . Reliability , clinical psychometric validity questionnaire assess correlation analysis , exploration know group comparison , responsiveness clinical change .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum No brain metastases intracranial tumor extension cognitive impairment PATIENT CHARACTERISTICS : No limit performance status Able understand language questionnaire No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule No concurrent malignancy except basal cell carcinoma skin PRIOR CONCURRENT THERAPY : No prior participation study ( different subgroup ) No concurrent participation quality life study might interfere study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>